BAY1238097 manufacturers
- BAY1238097
-
- $47.00
-
2026-07-15
- CAS:1564268-08-1
- Purity: 98.10%
- Supply Ability: 10g
- BAY1238097
-
- $47.00
-
2026-07-15
- CAS:1564268-08-1
- Purity: 98.10%
- Supply Ability: 10g
|
| | BAY1238097 Basic information |
| Product Name: | BAY1238097 | | Synonyms: | BAY1238097;3H-2,3-Benzodiazepine-3-carboxamide, 4,5-dihydro-7,8-dimethoxy-N,4-dimethyl-1-[4-(4-methyl-1-piperazinyl)phenyl]-, (4S)-;BAY1238097,BAY-1238097 | | CAS: | 1564268-08-1 | | MF: | C25H33N5O3 | | MW: | 451.56 | | EINECS: | | | Product Categories: | | | Mol File: | 1564268-08-1.mol |  |
| | BAY1238097 Chemical Properties |
| density | 1.22±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 150 mg/mL (332.18 mM) | | pka | 15.43±0.60(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | BAY1238097 Usage And Synthesis |
| Uses | BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 nM). | | in vivo | BAY 1238097 shows strong efficacy in the AML and MM models. BAY 1238097 has in vivo anti-tumour activity in lymphoma models[1][2].
BAY 1238097 is well tolerated at 10-15 mg/kg applied daily over 9-14 days in different disease models, with no obvious toxicity[1][2].
| Animal Model: | Severe combined immunodeficiency (SCID) female mice (9-12 weeks old) inoculated subcutaneously into the right flank with 5×106 SU-DHL-8 cells/mouse suspended in 0.1 mL of matrigel or with O | | Dosage: | 15 mg/kg (maximal tolerated dose). | | Administration: | Orally daily for 12 days (on day 21 post-tumour inoculation). | | Result: | Showed strong efficacy in the AML models THP-1, MOLM-13 and KG-1, with T/C between 13 and 20%. Also active in MM models in a human IGH-cyclin D1 translocated MOLP-8 model with a T/C of 3%[2].
|
| | References | [1] Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.
[2] Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. DOI:10.1111/bjh.14803 |
| | BAY1238097 Preparation Products And Raw materials |
|